# Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

> **NCT00387322** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 42 (actual)

## Conditions studied

- Lung Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** pemetrexed disodium

## Key facts

- **NCT ID:** NCT00387322
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-10
- **Final completion:** 2009-05
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2010-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00387322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00387322, "Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00387322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*